Suppr超能文献

四氢吡啶 LIMK 抑制剂:结构活性研究与生物学特性分析。

Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterization.

机构信息

ICOA, Université d'Orléans, CNRS UMR 7311, 45067, Orléans, France.

Centre de Biophysique Moléculaire, CNRS UPR4301, 45071, Orléans, France.

出版信息

Eur J Med Chem. 2024 May 5;271:116391. doi: 10.1016/j.ejmech.2024.116391. Epub 2024 Apr 9.

Abstract

LIM Kinases, LIMK1 and LIMK2, have become promising targets for the development of inhibitors with potential application for the treatment of several major diseases. LIMKs play crucial roles in cytoskeleton remodeling as downstream effectors of small G proteins of the Rho-GTPase family, and as major regulators of cofilin, an actin depolymerizing factor. In this article we describe the conception, synthesis, and biological evaluation of novel tetrahydropyridine pyrrolopyrimidine LIMK inhibitors. Homology models were first constructed to better understand the binding mode of our preliminary compounds and to explain differences in biological activity. A library of over 60 products was generated and in vitro enzymatic activities were measured in the mid to low nanomolar range. The most promising derivatives were then evaluated in cell on cofilin phosphorylation inhibition which led to the identification of 52 which showed excellent selectivity for LIMKs in a kinase selectivity panel. We also demonstrated that 52 affected the cell cytoskeleton by disturbing actin filaments. Cell migration studies with this derivative using three different cell lines displayed a significant effect on cell motility. Finally, the crystal structure of the kinase domain of LIMK2 complexed with 52 was solved, greatly improving our understanding of the interaction between 52 and LIMK2 active site. The reported data represent a basis for the development of more efficient LIMK inhibitors for future in vivo preclinical validation.

摘要

LIM 激酶(LIMKs),包括 LIMK1 和 LIMK2,已成为开发抑制剂的有前途的靶点,具有治疗几种主要疾病的潜力。LIMKs 作为 Rho-GTPase 家族小分子 G 蛋白的下游效应物,以及对丝切蛋白(一种肌动蛋白解聚因子)的主要调节物,在细胞骨架重塑中发挥着关键作用。在本文中,我们描述了新型四氢吡啶吡咯并嘧啶 LIMK 抑制剂的概念、合成和生物学评价。首先构建了同源模型,以更好地理解我们初步化合物的结合模式,并解释生物学活性的差异。生成了超过 60 种产品的文库,并在中等到低纳摩尔范围内测量了体外酶活性。然后,对最有前途的衍生物进行了共肌动蛋白磷酸化抑制的细胞评估,这导致鉴定出 52 种在激酶选择性小组中对 LIMKs 具有极好选择性的衍生物。我们还证明了 52 通过干扰肌动蛋白丝来影响细胞细胞骨架。使用三种不同细胞系的该衍生物的细胞迁移研究显示出对细胞迁移的显著影响。最后,解决了与 52 复合的 LIMK2 激酶结构域的晶体结构,极大地提高了我们对 52 和 LIMK2 活性位点之间相互作用的理解。所报道的数据为开发用于未来体内临床前验证的更有效的 LIMK 抑制剂提供了基础。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验